Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Prospective Randomized Study of MaioRegenTM Prime vs. Debridement (Surgical Standard of Care (SSOC)) for the Treatment of Osteochondral Lesion of the Knee Joint - OSTEOCONFIRM Study

NCT07332182 is registered in ClinicalTrials.gov with Fin-Ceramica Faenza Spa as lead sponsor.

NCT NCT07332182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07332182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Prospective Randomized Study of MaioRegenTM Prime vs. Debridement (Surgical Standard of Care (SSOC)) for the Treatment of Osteochondral Lesion of the Knee Joint - OSTEOCONFIRM Study
Lead sponsor
Fin-Ceramica Faenza Spa
Phase
Not applicable
Overall status
Recruiting
Start date
September 30, 2026
Completion date
April 30, 2031
Enrollment
400 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

early osteoarthritis, osteochondral lesions of the knee joint, osteochondritis dissecans (ocd)